Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
### Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut Syndrome (LGS).
### Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week, as tolerated, to a target dose of 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg per day).
### Pediatric Dosing
* **Children 2 to less than 10 years:**
* **Initial Dose:** 5 mg once daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week, as tolerated, to a target dose of 5 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg per day).
* **Children 10 years or older:** Dosing is the same as adults.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Data is limited, but dose reduction may be necessary.
* **Renal Impairment:** Use with caution. Data is limited, but dose reduction may be necessary.
* **Concomitant CYP2C19 Inhibitors:** Dose reduction may be required due to increased exposure.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, pyrexia, gait disturbance, fatigue, vomiting, upper respiratory tract infection, drooling, cough.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome), suicidal behavior or ideation, withdrawal symptoms, respiratory depression, dependence, abuse potential.
### Key Drug Interactions
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** Increased clobazam levels. Consider dose reduction of clobazam.
* **CYP2C19 Inducers (e.g., rifampin, carbamazepine):** Decreased clobazam levels. Consider dose increase of clobazam.
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Additive CNS depressant effects.
* **Lacosamide:** Increased risk of adverse events, including somnolence.
* **Valproic acid:** Clobazam may increase valproic acid concentrations; monitor valproic acid levels.
### Monitoring
* Monitor for somnolence and fatigue, especially during dose titration.
* Monitor for signs of suicidal behavior or ideation.
* Monitor for signs of withdrawal upon discontinuation.
* Monitor for respiratory depression, especially when used with other CNS depressants.
* If used with valproic acid, monitor valproic acid serum concentrations.
### Clinical Pearls
* Clobazam is typically used as adjunctive therapy and should be initiated and titrated slowly to minimize adverse effects.
* Withdrawal symptoms can occur upon abrupt discontinuation; taper the dose gradually.
* Due to the risk of severe skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
* Clobazam is a Schedule IV controlled substance.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines for complete details and to verify dosing and safety information before administering any medication.
